CombiMatrix Revenues Tumble 76 Percent in Q4; CMDX CEO Watson Steps Down | GenomeWeb
NEW YORK (GenomeWeb News) — CombiMatrix today said that fourth-quarter revenue plunged 76 percent as R&D spending jumped 24 percent and net loss widened 150 percent.
The company also said it has named Mansoor Mohammed to be CEO of CombiMatrix subsidiary CombiMatrix Molecular Diagnostics, replacing Matt Watson, who stepped down to “pursue other opportunities.” Mohammed had been president and COO of CMDX.
CMDX said Watson will remain a consultant to the company for three months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.